{"id":617291,"date":"2022-09-19T17:28:01","date_gmt":"2022-09-19T17:28:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=617291"},"modified":"2022-09-19T17:28:01","modified_gmt":"2022-09-19T17:28:01","slug":"acromegaly-market-to-observe-stupendous-growth-during-the-forecast-period-2032-delveinsight-amryt-mycapssa-crinetics-paltusotine-ionis-ionisghrlrx-camurus-aquestive-peptron","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/acromegaly-market-to-observe-stupendous-growth-during-the-forecast-period-2032-delveinsight-amryt-mycapssa-crinetics-paltusotine-ionis-ionisghrlrx-camurus-aquestive-peptron_617291.html","title":{"rendered":"Acromegaly Market to Observe Stupendous Growth During the Forecast Period (2032) – DelveInsight | Amryt (Mycapssa), Crinetics (Paltusotine), Ionis (IONIS-GHR-LRX), Camurus, Aquestive, Peptron"},"content":{"rendered":"
\n
\"Acromegaly<\/a><\/div>\n
\n
Delveinsight Business Research LLP<\/div>\n<\/div>\n<\/div>\n
As per the DelveInsight, the Acromegaly market size was found to be USD 956.96 Million in 2017 in the 7MM. The acromegaly market is anticipated to grow in the coming years owing to the increasing prevalent population of Acromegaly in the 7MM and the launch of emerging therapies.<\/div>\n

Globally, about 15+ key pharma and biotech companies<\/strong> are working in the Acromegaly therapeutics landscape<\/strong> based on different Routes of Administration (RoA), Mechanism of Action (MoA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.<\/em><\/p>\n

DelveInsight’s “Acromegaly Market Insights, Epidemiology, and Market Forecast 2032<\/strong>” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Acromegaly Market size, share, and trends in the seven major market (7MM) (i.e., the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).<\/p>\n

The Acromegaly market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice\/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. <\/p>\n

\"\"<\/p>\n

Acromegaly: An Overview<\/strong><\/p>\n

Acromegaly is a rare but serious condition caused by too much growth hormone (GH)<\/strong> in the blood. GH is released into the bloodstream by the pituitary gland, located at the base of the brain. The blood carries GH to other body parts, where it has specific effects. In children, GH stimulates growth and development. In adults, GH affects energy levels, muscle strength, bone health, and one’s sense of well-being. Too much GH in children is called gigantism and is extremely rare. Acromegaly in adults occurs mainly in middle-aged men and women.<\/p>\n

Acromegaly is a very rare condition, and each year, about three new cases of acromegaly occur for every million people.<\/strong><\/em><\/p>\n

Acromegaly Market Key Facts<\/strong><\/p>\n

• As per DelveInsight analysis, there was a total of 64,508<\/strong> Acromegaly prevalent cases in 2017.<\/em><\/p>\n

• In the case of the United States, the prevalent population was estimated to be 28,671<\/strong> in 2017.<\/em><\/p>\n

• In the EU5, the highest prevalent cases were reported to be in Germany<\/strong>, followed by the United Kingdom<\/strong> and France<\/strong>, whereas the lowest prevalence rates were reported in Spain<\/strong>.<\/em><\/p>\n

Acromegaly Market<\/strong><\/a><\/p>\n

The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted Acromegaly market size<\/strong> by analyzing the impact of current and emerging pipeline therapies. It also provides a thorough assessment of the market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.<\/p>\n

The report gives complete detail of the Acromegaly market trend<\/strong> for each marketed drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MoA), Route of Administration (RoA), molecule types, competition with other therapies, brand value, and their impact on the market.<\/p>\n

Acromegaly Epidemiology<\/strong><\/p>\n

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pool, future trends, and and views of key opinion leaders. <\/p>\n

Acromegaly Drugs Uptake and Pipeline Development Activities<\/strong><\/p>\n

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Acromegaly market<\/strong> or expected to get launched during the study period. The analysis covers Acromegaly market uptake by drugs, patient uptake by therapies, and sales of each drug. <\/p>\n

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.<\/p>\n

The report also covers the Acromegaly Pipeline Development Activities<\/strong>. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.<\/p>\n

Key Developments in the Acromegaly Therapeutic Market<\/strong><\/p>\n

• On September 16, 2022, Amryt (Nasdaq: AMYT)<\/strong> announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) had recommended the approval of Mycapssa®<\/strong> in the European Union (EU) for the maintenance treatment of acromegaly. The approval is for the patients who have responded to and tolerated treatment with octreotide or lanreotide. Mycapssa®<\/strong> is already approved in the United States for long-term maintenance treatment in acromegaly patients who have responded to and tolerated treatment with injectable octreotide or lanreotide.<\/em><\/p>\n

The Acromegaly market is expected to grow by factors like an increase in the prevalent pool, expected entry of emerging therapies with novel targets and attractive pricing, expected launch of Octreotide capsules, and more penetration in the 7MM markets.<\/p>\n

Learn How Acromegaly Market Will Evolve by 2032 @ https:\/\/www.delveinsight.com\/sample-request\/acromegaly-market<\/a><\/strong><\/p>\n

Acromegaly Therapeutics Analysis<\/strong><\/p>\n

There are approx. 15+ key companies<\/strong> which are developing therapies for Acromegaly. Currently, Crinetics Pharmaceuticals<\/strong> has its Acromegaly drug candidates in the most advanced stage of clinical development.<\/em><\/p>\n

Some of the key companies in the Acromegaly Therapeutic Market Include:<\/strong><\/p>\n

• Ionis Pharmaceuticals<\/p>\n

• Crinetics Pharmaceuticals<\/p>\n

• Camurus<\/p>\n

• Ono Pharmaceutical<\/p>\n

• Aquestive Therapeutics<\/p>\n

• Strongbridge Biopharma<\/p>\n

• Italfarmaco<\/p>\n

• Ipsen<\/p>\n

• Antisense Therapeutics<\/p>\n

• Dauntless Pharmaceuticals<\/p>\n

• TTY Biopharm<\/p>\n

• Peptron<\/p>\n

• DexTech Medical AB<\/p>\n

• Rani Therapeutics<\/p>\n

• OPKO Health, Inc.<\/p>\n

• Amolyt Pharma<\/p>\n

• Foresee Pharmaceuticals<\/p>\n

• ADVANZ PHARMA<\/p>\n

• Chiasma Pharma<\/p>\n

And many others<\/p>\n

 <\/p>\n

Acromegaly Emerging Drugs Covered in the report include:<\/strong><\/p>\n

• IONIS-GHR-LRX: Ionis Pharmaceuticals<\/p>\n

• Paltusotine: Crinetics Pharmaceuticals<\/p>\n

• Octreotide Capsules<\/p>\n

• ATL1103<\/p>\n

And many more<\/p>\n

Further Emerging Drugs & Key Companies are Covered in the Report. Download the Sample PDF to Learn More – <\/strong><\/p>\n

https:\/\/www.delveinsight.com\/sample-request\/acromegaly-market<\/strong><\/a><\/p>\n

 <\/p>\n

Table of Content (TOC)<\/strong><\/p>\n

1. Key Insights<\/p>\n

2. Executive Summary <\/p>\n

3. Acromegaly Competitive Intelligence Analysis<\/p>\n

4. Acromegaly Market Overview at a Glance<\/p>\n

5. Acromegaly Disease Background and Overview<\/p>\n

6. Acromegaly Patient Journey<\/p>\n

7. Acromegaly Epidemiology and Patient Population (In US, EU5, and Japan)<\/p>\n

8. Acromegaly Treatment Algorithm, Current Treatment, and Medical Practices<\/p>\n

9. Acromegaly Unmet Needs<\/p>\n

10. Key Endpoints of Acromegaly Treatment<\/p>\n

11. Acromegaly Marketed Products<\/p>\n

12. Acromegaly Emerging Drugs and Latest Therapeutic Advances<\/p>\n

13. Acromegaly Seven Major Market Analysis<\/p>\n

14. Attribute Analysis<\/p>\n

15. Acromegaly Market Outlook (In US, EU5, and Japan)<\/p>\n

16. Acromegaly Access and Reimbursement Overview<\/p>\n

17. KOL Views on the Acromegaly Market<\/p>\n

18. Acromegaly Market Drivers<\/p>\n

19. Acromegaly Market Barriers<\/p>\n

20. Appendix<\/p>\n

21. DelveInsight Capabilities<\/p>\n

22. Disclaimer<\/p>\n

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.<\/em><\/p>\n

Download Sample PDF to Explore the Key Offerings of the Report: 
<\/strong><\/p>\n

https:\/\/www.delveinsight.com\/sample-request\/acromegaly-market<\/strong><\/a><\/p>\n

 <\/p>\n

About DelveInsight
<\/strong>DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.<\/p>\n

Other Trending Healthcare Reports By DelveInsight<\/strong><\/p>\n

Keratitis Market<\/a><\/strong><\/p>\n

The “Keratitis Market” research report by DelveInsight provides a detailed overview of the historical and forecasted epidemiology as well as the Keratitis Market size, share, and trends in the 7MM (i.e. the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan). Additionally, it also covers the latest innovations, breakthroughs, emerging therapies, and key companies operating in the therapeutics market.<\/p>\n

Media Contact<\/span>
Company Name:<\/strong> DelveInsight Business Research LLP<\/a>
Contact Person:<\/strong> Shruti Thakur
Email:<\/strong> Send Email<\/a>
Phone:<\/strong> 09650213330
Address:<\/strong>304 S. Jones Blvd #2432
City:<\/strong> Las Vegas
State:<\/strong> NV
Country:<\/strong> United States
Website:<\/strong> https:\/\/www.delveinsight.com\/<\/a><\/p>\n

<\/object>\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

Delveinsight Business Research LLP As per the DelveInsight, the Acromegaly market size was found to be USD 956.96 Million in 2017 in the 7MM. The acromegaly market is anticipated to grow in the coming years owing to the increasing prevalent … Continue reading →<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,425,426,417,404],"tags":[],"class_list":["post-617291","post","type-post","status-publish","format-standard","hentry","category-Business","category-Finance","category-Financial-Market","category-Marketing-Sales","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/617291","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=617291"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/617291\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=617291"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=617291"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=617291"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}